Predictors of inactive disease in patients after newly starting treatment with TNF-α inhibitor. OR < 1 signify decreased odds of attaining inactive disease.
| Outcome | Predictors | Univariate OR (95% CI) | Multivariable Model OR (95% CI) |
|---|---|---|---|
| Inactive disease at 1-year followup | ERA (vs RF-negative poly) | 0.23 (0.07, 0.84) | 0.20 (0.07–0.56) |
| Baseline CHAQ < 1 | 4.1 (1.4, 13) | 5.7 (1.7–19) | |
| Active enthesitis | 0.36 (0.13, 0.96) | — | |
| Inactive disease ever | ERA (vs RF-negative poly) | 0.24 (0.07, 0.82) | 0.24 (0.08–0.75) |
| Baseline CHAQ < 1 | 2.8 (1.2, 6.7) | 6.0 (1.6–23) | |
| Normal ESR at baseline | 0.43 (0.17, 1.1) | — | |
| Active enthesitis | 0.43 (0.20, 0.95) | — | |
| No. followup visits | 1.4 (1.1, 1.7) | 1.5 (1.1–2.1) |
TNF-α: tumor necrosis factor-α; RF: rheumatoid factor; ERA: enthesitis-related arthritis; ESR: erythrocyte sedimentation rate; CHAQ: Childhood Health Assessment Questionnaire.